Q4 2019 EPS Estimates for Charles River Laboratories Intl. Inc (NYSE:CRL) Increased by Analyst

Charles River Laboratories Intl. Inc (NYSE:CRL) – Stock analysts at KeyCorp raised their Q4 2019 earnings per share estimates for Charles River Laboratories Intl. in a report released on Wednesday, November 6th. KeyCorp analyst D. Hooker now forecasts that the medical research company will post earnings per share of $1.83 for the quarter, up from their previous forecast of $1.82.

Several other brokerages have also issued reports on CRL. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. UBS Group decreased their target price on Charles River Laboratories Intl. from $147.00 to $145.00 and set a “neutral” rating for the company in a research report on Thursday. Zacks Investment Research lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. SunTrust Banks raised their price objective on Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Finally, Bank of America lowered Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price objective for the company. in a research report on Friday, October 18th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and a consensus target price of $150.50.

Shares of NYSE:CRL opened at $130.51 on Friday. Charles River Laboratories Intl. has a 52-week low of $103.00 and a 52-week high of $149.07. The firm has a market capitalization of $6.23 billion, a P/E ratio of 21.64, a P/E/G ratio of 2.00 and a beta of 1.08. The stock has a 50 day moving average price of $132.15 and a 200-day moving average price of $133.41. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.05. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The firm had revenue of $668.00 million during the quarter, compared to analyst estimates of $674.08 million. During the same quarter in the prior year, the company earned $1.53 EPS. The business’s revenue was up 14.1% compared to the same quarter last year.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Charles River Laboratories Intl. by 1.6% in the 2nd quarter. BlackRock Inc. now owns 4,660,628 shares of the medical research company’s stock worth $661,344,000 after buying an additional 72,827 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Charles River Laboratories Intl. by 7.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,239,921 shares of the medical research company’s stock worth $317,845,000 after buying an additional 157,160 shares during the last quarter. TimesSquare Capital Management LLC boosted its stake in shares of Charles River Laboratories Intl. by 11.0% in the 3rd quarter. TimesSquare Capital Management LLC now owns 1,007,750 shares of the medical research company’s stock worth $133,396,000 after buying an additional 99,900 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Charles River Laboratories Intl. by 49.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock worth $138,804,000 after buying an additional 323,625 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Charles River Laboratories Intl. by 5.1% in the 2nd quarter. Bank of America Corp DE now owns 471,966 shares of the medical research company’s stock worth $66,972,000 after buying an additional 22,821 shares during the last quarter. Hedge funds and other institutional investors own 94.31% of the company’s stock.

In other news, insider David Ross Smith sold 1,249 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $130.36, for a total value of $162,819.64. Following the transaction, the insider now directly owns 19,327 shares in the company, valued at approximately $2,519,467.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.80% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Analyzing a company’s cash flow statement

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.